## Christophe Ferrand

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7237998/publications.pdf

Version: 2024-02-01

		623574	752573
19	765	14	20 g-index
papers	citations	h-index	g-index
22	22	22	1100
23	23	23	1129
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia., 2022, 10, e004222.		14
2	Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Advances, 2021, 5, 1540-1551.	<b>2.</b> 5	35
3	Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients. Journal of Translational Medicine, 2021, 19, 265.	1.8	20
4	Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch. Cancer Gene Therapy, 2021, 28, 1365-1375.	2.2	18
5	Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses. Science Signaling, 2020, 13, .	1.6	47
6	Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. Frontiers in Oncology, 2020, 10, 599933.	1.3	15
7	EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung Carcinomas. Cancers, 2020, 12, 3649.	1.7	15
8	CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. Leukemia, 2020, 34, 3228-3241.	3.3	27
9	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. Blood Advances, 2019, 3, 4238-4251.	2.5	72
10	CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor–Engineered T Cells. Cancer Research, 2019, 79, 663-675.	0.4	62
11	Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies. Experimental Hematology and Oncology, 2018, 7, 5.	2.0	2
12	IL-21–Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor–Dependent Manner. Journal of Immunology, 2016, 197, 85-96.	0.4	30
13	Involvement and prognosis value of CD8 + T cells in giant cell arteritis. Journal of Autoimmunity, 2016, 72, 73-83.	3.0	56
14	New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. Experimental Hematology and Oncology, 2015, 5, 7.	2.0	17
15	Preferential splenic CD8+ T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. Blood, 2013, 122, 2477-2486.	0.6	42
16	Systematic donor blood qualification by flow cytometry would have been able to avoid CLLâ€type MBL transmission after unrelated hematopoietic stem cell transplantation. European Journal of Haematology, 2012, 88, 269-272.	1.1	9
17	Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. British Journal of Haematology, 2009, 145, 624-636.	1.2	163
18	Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood, 2004, 105, 1256-1264.	0.6	83

#	Article	IF	CITATIONS
19	How should chimerism be decoded?1. Transplantation, 2003, 75, 50S-54S.	0.5	11